Sommaire
Littérature scientifique sur le sujet « Peptide amiloide-β »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Peptide amiloide-β ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Peptide amiloide-β"
Bognanni, Noemi, Francesco Bellia, Maurizio Viale, Nadia Bertola et Graziella Vecchio. « Exploring Charged Polymeric Cyclodextrins for Biomedical Applications ». Molecules 26, no 6 (19 mars 2021) : 1724. http://dx.doi.org/10.3390/molecules26061724.
Texte intégralZhytniakivska, Olga, Uliana Tarabara, Atanas Kurutos, Kateryna Vus, Valeriya Trusova et Galyna Gorbenko. « Molecular Docking of Monomethine Cyanine Dyes to Lysozyme Amyloid Fibrils ». 3, no 3 (2 septembre 2022) : 142–48. http://dx.doi.org/10.26565/2312-4334-2022-3-18.
Texte intégralRomero Ramos, Nestor, Óscar Romero-Ramos et Arnoldo José González Suárez. « Actividad física y funciones cognitivas en personas mayores : revisión sistemática de los últimos 5 años (Physical activity and cognitive functions in older people : a systematic review of the last 5 years) ». Retos, no 39 (2 août 2020). http://dx.doi.org/10.47197/retos.v0i39.79960.
Texte intégralMartínez-Díaz, Jorge Antonio, María Elena Hernández-Aguilar, Fausto Rojas-Durán, Deissy Herrera-Covarrubias, Luis Isauro García-Hernández, Sonia Lilia Mestizo-Gutiérrez et Gonzalo Emiliano Aranda-Abreu. « Expression of proteins linked to Alzheimer’s disease in C6 rat glioma cells under the action of lipopolysaccharide (LPS), nimesulide, resveratrol and citalopram ». Turkish Journal of Biochemistry, 28 août 2020. http://dx.doi.org/10.1515/tjb-2020-0091.
Texte intégralThèses sur le sujet "Peptide amiloide-β"
VILARDO, ELISA. « Il microRNA-101 regola la proteina precursore del peptide β-amiloide ». Doctoral thesis, Università degli Studi di Roma "Tor Vergata", 2010. http://hdl.handle.net/2108/1175.
Texte intégralIn the pathogenesis of Alzheimer's disease, the expression level of the β-amyloid precursor protein (APP) plays a crucial role. It has been shown that mutations which increase APP protein synthesis, including the duplication of the locus of APP gene in certain families and trisomy of chromosome 21 (containing the APP gene), are sufficient to induce the early form of pathology. Therefore APP gene regulation has been extensively studied and both the promoter and 5’ and 3’ untranslated regions of mRNA have been charachterised. In recent years, the post-transcriptional mechanism of gene expression mediated by microRNAs has been discovered and investigated in several biological mechanisms and cell types. MicroRNAs have been shown to finely modulate the translation of proteins needed for the response to extracellular stimuli, and to define the spatial and temporal expression profiles of genes involved in neuronal development and differentiation. This experimental thesis focused on the question whether microRNAs are significantly involved in APP regulation. Through RNAi , Argonauta-2 gene, a key component of the ribonucleoprotein complex mediating the action of microRNAs, was silenced and APP protein increase was observed. Through bioinformatic analysis, microRNAs potentially interacting with APP have been identified and miR-101, which is enriched in the nervous system, was further investigated. Through expression analysis in rat hippocampus, from 8 days up to 6 months of age, it was observed an inverse correlation between miR-101 levels, which increase, and APP expression, which decreases over time. Using a reporter construct, the ability of miR-101 to inhibit the translation of APP through direct interaction with the messenger 3’UTR was demonstrated. Through inhibition of miR-101 in hippocampal primary cultures, a significant increase of endogenous APP protein was observed, confirming the miRNA regulatory function in the neuronal context. Instead miR-101 over-expression was effective in inducing APP repression at post-transcriptional level. It was also observed that stimulation of hippocampal neurons with IL-1, the first player of neuroinflammation and risk factor for Alzheimers Disease, induces coordinated modulation of APP and miR-101. These data demonstrate the repressive effect of miR-101 on APP under physiological conditions, while the alteration of this regulation is sufficient to induce an increase of APP protein, a condition which is associated to familial Alzheimer’s disease. In view of previous studies, in which miR-101 was shown to be down-regulated in the brains of sporadic cases of Alzheimer's disease, and of data obtained in this work, miR-101 may be a protective regulator of excessive production of β-amyloid precursor protein. The characterization of the signal transduction pathway activated by neuroinflammation, involving miR-101, and the relationship between this pathway and Alzheimer's disease might open a new perspective on the pathogenesis of this neurodegenerative disease.
RIZZA, FABIO. « Structural modelling of biological macromolecules : the cases of neurofibromin, bifurcating Electron Transferring Flavoprotein and Amyloid-β (1-16) peptide ». Doctoral thesis, Università degli Studi di Milano-Bicocca, 2021. http://hdl.handle.net/10281/310480.
Texte intégralIn this thesis, three independent projects were addressed, sharing the computational approach based on molecular modeling and in particular molecular dynamics. In the first project, the Sec14-PH domain of neurofibromin (NF1) was investigated. The Sec14 domains have been identified in many different proteins, from prokaryotes to humans, serving as exchangers of lipid molecules between membranes, by means of a pocket whose opening is allowed by the motion of a specific alpha-helix (called lid helix). The crystal structure of the NF1-Sec14 domain (of both the wild type and some mutants associated with the onset of neurofibromatosis pathology) has revealed its peculiarity of being structurally coupled to a PH domain that strongly interacts with the lid helix through a long loop (called lid-lock loop). On this basis, a mechanism for the opening of the Sec14 lipid pocket was formulated which would involve a concerted movement of the lid-lock loop, but this movement has actually never been shown. Guided by available experimental data on the thermal denaturation of Sec14-PH domain of NF1, both on the wild type and some neurofibromin-related mutants, several simulations at high temperature were carried out to compare the dynamics of the wild type domain with a pathological mutant associated with the onset of neurofibromatosis. Our simulations lead us to suggest an opening mechanism for the lid helix and provide a hypothesis for the structural and dynamic basis of the onset of the disease in the case of the specific mutant. The second project addressed the study of a protein called EtfAB which catalyzes a recently discovered process known as Flavin-Based Electron Bifurcation (FBEB). This mechanism is only exploited by some anaerobic microorganisms as a third way of energy coupling. So far, four unrelated protein families are known that are able to catalyze FBEB. Among these, EtfAB, catalyzes the electron transfer between the two FAD molecules bound to it. Surprisingly, the distance between these two FADs, as observed in the crystal structure of EtfAB, is 18 Å, whereas biological electron transfer is considered more likely to occur at a maximal distance of 14 Å. To explain this, a possible mechanism has been suggested that could bring the two FAD molecules closer together. Using molecular dynamics, it was possible to test, and discard, the proposed mechanism. Furthermore, with the Density Functional Theory (DFT), it was possible to provide an interpretation to some spectroscopic data regarding the possible electron transfer between the two FAD molecules. In the third project, I collaborated with Prof. Luca Bertini on a project on the production and propagation of some reactive oxygen species (ROS) in the context of the amyloid-beta peptide involved in the pathogenesis of Alzheimer's. In the amyloid hypothesis on the onset of Alzheimer's disease, an important role has been attributed to the damage caused by ROS, produced by a metal ion coordinated to the amyloid peptide itself, in particular by the hydroxyl radical (OH.-). However, the details of how these radicals propagate and react have not yet been clarified. While Prof. Bertini's DFT calculations addressed the oxidative capacities of the hydroxyl radical and the possible reaction products in the context of the amyloid-beta peptide, my molecular dynamics simulations provided an overview on which possible targets of the hydroxyl radical, coordinated to the ion Cu of the complex, could actually react with the hydroxyl radical due to the dynamic motions of the peptide.
Klementieva, Oxana. « Influence of Cu(II) and Glycodendrimers on Amyloid-beta-Peptide Aggregation ». Doctoral thesis, Universitat Internacional de Catalunya, 2012. http://hdl.handle.net/10803/78910.
Texte intégralSenile plaques of Alzheimer’s disease patients are composed primarily of the amyloid-β-peptide (Aβ). Recent studies implicate Cu(II) in the aetiology of AD. The role of Cu(II) in ADis currently highly disputed. Influence of Cu(II) on Aβ aggregation and amyloidogenic properties of glycodendrimers were investigated in this thesis. AFM, TEM, SEM, SAXS, FTIR and fluorescence spectroscopy were used to study a morphology and a secondary structure of Aβ-Cu(II) aggregates. The toxic effects of Aβ40-Cu(II) amorphous aggregates was confirmed for neuronal cell lines. It was shown that maltose glycodendrimers can be efficiently used to modulate Alzheimer’s amyloid peptide aggregation and inhibit cell toxicity by facilitating the clustering of amyloid fibrils. These results show that glycodendrimers are promising non-toxic agents in the search for anti-amyloidogenic compounds. It was also suggested that fibril clumping may be anti-amyloid toxicity strategy.
Bosch, Morató Mònica 1986. « The Role of intracellular amyloid β-peptide in the pathophysiology of GNE myopathy and Alzheimer's disease ». Doctoral thesis, Universitat Pompeu Fabra, 2015. http://hdl.handle.net/10803/650351.
Texte intégralEl pèptid β-amiloide (Aβ) s’acumula en diverses malalties com la miopatia de GNE i la Malaltia d’Alzheimer (MA). La miopatia de GNE és una malaltia del múscul esquelètic causada per mutacions al gen UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE), que codifica un enzim clau en la biosíntesis de l’àcid siàlic. El GNE mutat produeixen un enzim hipofuncional i una conseqüent disminució de l’àcid siàlic cel·lular. Hem vist que la hiposialització afavoreix l’endocitosi de l’Aβ en cèl·lules musculars, la qual és dependent de clatrina i de l’heparà sulfat proteoglicà. A més, hem observat que l’Aβ intracel·lular indueix l’apoptosi en cèl·lules musculars mitjançant la inhibició de l’Akt. Així, la fosforilació de l’Akt es troba reduïda i l’apoptosi induïda en mioblasts d’un pacient amb la miopatia de GNE. Finalment, a través d’un cribratge del genoma complert de Saccharomyces cerevisiae, hem identificat nous moduladors de la toxicitat per Aβ que inclouen components de la cadena respiratòria mitocondrial i membres de la via de senyalització del Ca2+. En resum, aquest estudi ofereix una millor comprensió del rol de l’Aβ en la miopatia de GNE i la MA.
Ramos, Fernández Eva 1984. « The Physiopathological role of nitric oxide in the brain : from translational regulation of the GluN2B subunit to post-translational modifications of albumin in Alzheimer's disease ». Doctoral thesis, Universitat Pompeu Fabra, 2013. http://hdl.handle.net/10803/129925.
Texte intégralEl óxido nítrico (NO) es una molécula con efectos pleyotrópicos en cerebro y sistema vascular. Fisiológicamente, induce la traducción de la subunidad GluN2B del N-methyl D-aspartate receptor (NMDARc) al revertir la represión de su 5’untranslated region (5’UTR). Este efecto se debe a la activación de la heme regulated eIF2α kinase (HRI) y previene el exceso de GluN2B, especialmente en regiones extrasinápticas, donde desencadena excitotoxicidad. Patológicamente, el NO en un ambiente pro-oxidatvio como el dado en la enfermedad de Alzheimer (AD) reacciona con el anión superóxido produciendo peroxinitrito, y causando entre otros efectos la nitrotirosinación de proteínas. Simultaneamente, las proteínas de pacientes con AD padecen otros procesos oxidativos como la glicación. Por tanto, la albúmina, la proteína plasmática más abundante, en estos pacientes está más nitrotirosinada y glicada, afectando su estructura. La albúmina modificada presenta menos capacidad para tamponar la osmolaridad y apenas es digerida por las células de hepatoma. Además, une más Aβ, contribuyendo a mantener más alta la carga amiloidogénica en cerebro y plasma.
Souza, Ana Cristina Guerra de. « Papel protetor do 2-feniletinil-butilterúrio em modelos de dano cognitivo em camundongos e na apoptose em células humanas ». Universidade Federal de Santa Maria, 2013. http://repositorio.ufsm.br/handle/1/4467.
Texte intégralMemory is considered to be a process that has several stages, including acquisition, consolidation and retrieval. Memory impairment occurs when important synapses are modified. Alzheimer s disease (DA) is the most common cause of dementia. DA is characterized by cognitive damage, accumulation of the pathogenic amyloid-β (Aβ) peptide, and cholinergic dysfunction. Moreover, oxidative stress is associated with DA. Therapies used for dementia are still palliative rather than curative. Consequently, new therapies are urgently required. Biological effects of tellurium compounds have been studied, leading to a set of interesting and promising applications. Accordingly, 2-phenylethinyl-butyltellurium (PEBT), an organotellurium compound, has been reported as antioxidant. The purpose of this study was to characterize PEBT as a promising alternative for memory improvement and prevention of cognitive deficits, using experimental models of DA in mice. Initially, the present study was conducted to evaluate the effect of a single oral administration (p.o.) of PEBT at a dose of 10 mg/kg on memory, employing the step-down inhibitory avoidance task. PEBT administered 1 h before training, immediately after training or 1 h before the test session of the step-down inhibitory avoidance task increased the step-down latency time in comparison to the control mice, improving acquisition, consolidation, and retrieval of memory, respectively. The glutamate uptake, but not glutamate release, by cerebral cortex and hippocampal slices of mice was inhibited after 1 h of treatment with PEBT. After 24 h of PEBT exposure, the inhibition of cerebral cortex glutamate uptake disappeared. The improvement of memory by PEBT seems most likely to be mediated through an interaction with the amino acid transporters of the glutamatergic system. Thereafter, a subchronic PEBT treatment (1 mg/kg, p.o., for 10 days) after injection of Aβ(25-35) (3 nmol/3 μl/per site, intracerebroventricular) reversed Aβ-induced learning and memory deficits in the Morris water maze and step-down inhibitory avoidance tasks. In addition, PEBT (10 mg/kg, p.o.), administered 30 min before scopolamine (1 mg/kg, intraperitoneal), ameliorated memory deficit induced by this amnesic agent in the Morris water maze. Further, scopolamine was given 30 min before training and test or immediately post-training of step-down inhibitory avoidance task, inducing damage on acquisition, retrieval, and consolidation of memory, respectively. PEBT, administered 30 min before scopolamine, improved consolidation and retrieval stages, but not acquisition. General locomotor and exploratory activities, evaluated in the open-field test, were similar in all mice. Finally, the antiapoptotic effect of PEBT was evaluated. Human retinal pigment epithelial cells (ARPE-19 cell line) were exposed to in vitro oxidative stress by 10 ng/ml tumor necrosis factor-α and 600 μM H2O2. One hour PEBT incubation at concentrations of 7.5 and 10 μM attenuated the apoptosis induced by oxidative stress. This effect lasted up to 6 hours after oxidative stress induction. PEBT (5 and 10 μM) inhibited oxidative stress-induced poly (ADP-ribose) polymerase (PARP) cleavage and restored extracellular-signal-related kinase (ERK) phosphorylation decreased by oxidative stress. The protective mechanism exerted by PEBT against oxidative stress may involve PARP cleavage, regulation of ERK pathway, as well as its known antioxidant properties. In conclusion, the finds of the present thesis point out the ameliorative effect of PEBT on memory stages (acquisition, consolidation and retrieval). Likewise, PEBT improved memory impairment in mice. These effects seem to be due to strengthen the physiological glutamatergic tonus by PEBT and the antiapoptotic effect of PEBT. Therefore, PEBT could be considered a candidate for the prevention of memory deficits such as those observed in DA.
memória inclui pelo menos três tipos de processamento relacionados entre si: aquisição, consolidação e evocação. A memória é afetada quando as sinapses encarregadas de fazer ou evocar memórias encontram-se alteradas. A doença de Alzheimer (DA) é a causa mais comum de demência. A DA é caracterizada por danos cognitivos, acúmulo de peptídeo β-amiloide (Aβ) e disfunção colinérgica. Além disso, o estresse oxidativo está associado à DA. Uma vez que ainda não há cura para a DA e as terapias atuais são apenas paliativas, torna-se importante a busca de novos compostos para melhorar danos cognitivos. Com o estudo dos efeitos biológicos de compostos de telúrio, muitas aplicações estão sendo descobertas. Neste sentido, o composto orgânico de telúrio 2-feniletinil-butiltelúrio (PEBT) apresenta efeito antioxidante. O objetivo deste estudo foi caracterizar o PEBT como uma alternativa promissora para a melhora e prevenção de danos cognitivos, usando modelos experimentais da DA em camundongos. Primeiramente, avaliou-se o efeito de uma única dose oral (p.o) de PEBT (10 mg/kg) na memória, utilizando a tarefa da esquiva inibitória. O tratamento com PEBT 1 h antes do treino, imediatamente após o treino ou 1 h antes do teste da esquiva inibitória aumentou a latência comparada com os animais controles, melhorando a aquisição, consolidação e evocação da memória, respectivamente. A captação de glutamato, mas não a liberação deste neurotrasmissor, foi inibida em córtex e hipocampo de camundongos após 1 h de tratamento com PEBT. Após 24 h, a inibição da captação de glutamato no córtex não foi mais evidenciada. A melhora da memória causada pelo PEBT parece ser mediada através da interação com os transportadores de glutamato. Além disso, o tratamento subcrônico com PEBT (1 mg/kg, p.o., por 10 dias) após a injeção de Aβ(25-35) (3 nmol/3 μl/per site, intracerebroventricular) reverteu o prejuízo no aprendizado e na memória causados por Aβ nas tarefas do labirinto aquático de Morris e na esquiva inibitória. O PEBT (10 mg/kg, p.o.), adminstrado 30 min antes da escopolamina (1 mg/kg, intraperitoneal), também protegeu do dano de memória causado por este agente anticolinérgico no labirinto aquático de Morris. Quando a escopolamina foi administrada 30 min antes do treino ou teste, ou imediatamente após o treino da esquiva inibitória houve dano na aquisição, evocação e consolidação da memória, respectivamente. O PEBT, administrado 30 min antes da escopolamina, protegeu do dano na consolidação e evocação da memória, mas não na aquisição. Não houve diferença nas atividades locomotora e exploratória dos animais tratados com o PEBT no teste do campo aberto. Finalmente, o efeito antiapoptótico do PEBT foi avaliado. Células do epitélio pigmentado da retina humana (linhagem ARPE-19) foram expostas ao estresse oxidativo induzido pelo fator de necrose tumoral-α (10 ng/ml) e H2O2 (600 μM). O PEBT (7.5 e 10 μM), quando pré-incubado por 1 h, protegeu contra a apoptose induzida pelo estresse oxidativo e este efeito permaneceu até 6 h após a indução. O PEBT (5 e 10 μM) inibiu a clivagem da poli(ADP-ribose) polimerase (PARP) induzida por estresse oxidativo e, também, restaurou a fosforilação da quinase regulada por sinal extracelular (ERK). O efeito protetor do PEBT contra o estresse oxidativo parece envolver a clivagem da PARP e a regulação da fosforilaçao de ERK, além de sua atividade antioxidante. Nesse sentido, os resultados apresentados nesta tese destacam o efeito do PEBT na melhora das três fases da memória, bem como em modelos de dano cognitivos em camundongos. Estes resultados parecem estar relacionados ao aumento do tônus glutamatérgico causado pelo PEBT e seu efeito antiapoptótico. Assim sendo, estes dados sugerem que o PEBT poderá, futuramente, ser considerado candidato para a prevenção de danos de memória, como aqueles observados na DA.
Gomes, Guilherme Monteiro. « Modulação do sistema das poliaminas e bloqueio seletivo de correntes de K+ do tipo A reverte o dano cognitivo induzido por peptídeo β-amiloide25-35 ». Universidade Federal de Santa Maria, 2013. http://repositorio.ufsm.br/handle/1/4483.
Texte intégralIn Alzheimer s disease (AD), β-amyloid peptide (Aβ) has been linked with synaptic loss and cognitive dysfunction, albeit the precise mechanism remains unknown. An involvement of N-Methyl-D-Aspartate receptors (NMDAR) in AD is proposed, since its inhibition attenuates some aspects of AD s neuropathology. In this regard, polyamines, like spermidine and spermine, positive modulators of NMDARs, have been shown to have both concentration and synthesis increased by Aβ. Using the novel object recognition task we showed that negative modulation of polyamine system, been trough blockade of its binding site at NMDAR by arcaine (0.02 nmol/site), traxoprodil (0.002 nmol/site), or inhibition of polyamine synthesis by DFMO (2.7 nmol/site), reverses Aβ25-35-induced memory impairment in mice. The activation of polyamine binding site at NMDAR located at extrasynaptic sites might underlie the cognitive deficits of Aβ25-35-treated mice, since incubation of hippocampal neuron cultures with spermidine (400 μM) or Aβ25-35 (10 μM) significantly increased nuclear accumulation of jacob protein, a marker of extrasynaptic NMDAR activation. Moreover, traxoprodil (4nM), arcaine (4 μM) or DFMO (5 μM) blocked the Aβ-induced jacob nuclear translocation. Activation of extrasynaptic NMDAR in neurons leads to striping of synaptic contacts and simplification of neuronal cytoarchitecture. Incubation of hippocampal neuron cultures with traxoprodil (4 Nm), arcaine (4 μM) or DFMO (5 μM) reversed the deleterious effects of Aβ25-35 on dendritic spine number and spine morphology. We also evaluated the involvement of A-type K+ currents on the Aβ25-35-induced memory impairment. Administration of Tx3-1 (3 100 pmol/site), a selective IA blocker, restored memory of mice injected with Aβ25-35 and tested on the novel object recognition task The reversal of memory impairment and the protective effect on dendritic spine alterations exerted by the modulators of the polyamine system suggest the polyamine binding site at extrasynaptic NMDAR a potential player in Aβ-induced cognitive deficit.
O peptídeo β-amiloide (Aβ), reconhecido como agente tóxico na Doença de Alzheimer (DA) é implicado como causador de danos cognitivos e sinápticos, apesar de os mecanismos não serem completamente compreendidos. O envolvimento do receptor N-metil-D-aspartato (NMDA) na DA é sugerido, visto que o seu bloqueio atenua alguns aspectos neuropatológicos da DA. Nesse contexto, tem sido demonstrado que as poliaminas, como espermidina e espermina, moduladores positivos do receptor NMDA, possuem níveis e síntese elevada tanto no cérebro de pacientes com DA como em preparações in vitro utilizando o peptídeo Aβ. Neste estudo demonstrou-se que a modulação do sistema das poliaminas, através do bloqueio do seu sítio de ligação no receptor NMDA por arcaína (0,02 nmol/sítio), traxoprodil (0,002 nmol/sítio) ou da inibição de sua síntese por DFMO (2,7 nmol/sítio), reverte o déficit cognitivo induzido pela injeção de Aβ25-35 em camundongos testados na tarefa de reconhecimento de objetos. A ativação do sítio de ligação das poliaminas em receptores NMDA extrassinápticos pode subjazer o déficit cognitivo de camundongos injetados com Aβ25-35, visto que a incubação de culturas primárias de neurônios hipocampais com espermidina (400 μM), NMDA (200 μM) ou Aβ25-35 (10 μM) aumenta o acúmulo nuclear de jacob, um marcador de ativação de receptores NMDA extrassinápticos, de maneira significante. Ademais, traxoprodil (4 nM), arcaína (4 μM) ou DFMO (5 μM) bloquearam o acúmulo nuclear de jacob induzido por Aβ. A ativação de receptores NMDA extrassinápticos em neurônios leva a simplificação da citoarquitetura neuronal e a diminuição de contatos sinápticos. Aqui demonstrou-se que a incubação de culturas de neurônios hipocampais com traxoprodil (4 nM), arcaína (4 μM) ou DFMO (5 μM) reverte as alterações na a densidade e morfologia de espinhas dendríticas induzido pela incubação com Aβ25-35. Ainda, também avaliou-se o envolvimento de correntes de K+ do tipo A no déficit cognitivo induzido pela injeção i.c.v. de Aβ25-35. A administração de Tx3-1 (3 100 pmol/sítio), um bloqueador seletivo de correntes IA, reverteu o prejuízo de memória de camundongos injetados com Aβ25-35 e testados na tarefa de reconhecimento de objetos. A reversão dos danos cognitivos e sinápticos induzidos por Aβ25-35 através da modulação do sistema das poliaminas sugere a estimulação do sítio de ligação das poliaminas no receptor NMDA, possivelmente extrassínaptico, como um dos mecanimos por trás do déficit cognitivo induzido pelo peptídeo Aβ.
Oliveira, Elodie Morais. « Relatórios de Estágio e Monografia intitulada"A influência da infecção microbiológica no desenvolvimento da Doença de Alzheimer" ». Master's thesis, 2019. http://hdl.handle.net/10316/88275.
Texte intégralA Doença de Alzheimer (DA) é uma doença neurodegenerativa, considerada a principal causa de demência a nível mundial. Afeta essencialmente os idosos e está associada a alterações a nível da memória e da orientação espacial. Descrita pela primeira vez em 1907 pelo médico Aloysius Alzheimer, caracteriza-se pela deposição de peptídeo β-amiloide (Aβ) e proteína tau hiperfosforilada, sob a forma de placas senis e de aglomerados neurofibrilares (NFTs), respetivamente. A deteção destas proteínas anormais é essencial no diagnóstico da doença, uma vez que os sintomas da DA são semelhantes aos encontrados noutras patologias. Uma minoria dos doentes desenvolve a doença devido à presença específica de mutações genéticas na proteína precursora amiloide (APP) ou nas presenilinas 1 e 2 (PSEN1/PSEN2). Para os restantes casos estão já identificados alguns fatores de risco, contudo a causa exata é ainda desconhecida. A hipótese de que a DA tenha uma causa infeciosa encontra-se atualmente sob intensa investigação. De facto, alguns microorganismos têm a capacidade de permanecer no organismo na forma latente, causando uma infeção crónica. Ao longo da vida podem sofrer várias reativações, o que origina um estado inflamatório recorrente. O estado inflamatório está diretamente relacionado com a DA, pela ativação de mecanismos que contribuem para a deposição proteica. Por outro lado, verificou-se que o peptídeo Aβ poderá exercer atividade antimicrobiana contra vários agentes patogénicos, tais como os vírus Herpes Simples do tipo 1 e 2 (HSV-1/ HSV-2) ou Influenza, entre outros. A teoria antimicrobiana tenta explicar a etiologia da DA, associando o aumento da produção de peptídeo Aβ e a sua consequente deposição em resposta à presença crónica de determinados microorganismos no cérebro. A patologia amiloide observada na DA inicia-se vários anos antes do aparecimento dos primeiros sintomas, facto que se apresenta em concordância com esta teoria.
Alzheimer's Disease (AD) is a neurodegenerative disease, considered the leading cause of dementia worldwide. It primarily affects the elderly and is associated with changes in memory and spatial orientation. First described in 1907 by the doctor Aloysius Alzheimer, it is characterized by the deposition of β-amyloid peptide (Aβ) and hyperphosphorylated tau protein in the form of senile plaques and neurofibrillary agglomerates (NFTs), respectively. Detection of these abnormal proteins is essential in the diagnosis of the disease, since the symptoms of AD are similar to those found in other pathologies. A minority of patients develop the disease because of the specific presence of genetic mutations in the amyloid precursor protein (APP), or in presenilin’s 1 and 2 (PSEN1 / PSEN2). For the remaining cases, some risk factors have been identified, but the exact cause is still unknown. The hypothesis that AD has an infectious cause is currently under intense investigation. Indeed, some microorganisms have the ability to remain in the body in a latent form causing a chronic infection. Throughout an individual’s life they can undergo several reactivations, which gives rise to a recurrent inflammatory state. The inflammatory state is directly related to AD by the activation of mechanisms that contribute to protein deposition. On the other hand, the Aβ peptide has been shown to be able to exert antimicrobial activity against various pathogens, such as Herpes Simplex-1 and 2 (HSV-1 / HSV-2) or Influenza, among others. The antimicrobial theory attempts to explain the etiology of AD by associating the increase in Aβ production and its consequent deposition with the chronic existence of certain microorganisms in the brain. The amyloid pathology observed in AD begins several years before the appearance of the first symptoms, which is in agreement with this theory.
Actes de conférences sur le sujet "Peptide amiloide-β"
Azevedo, José Bruno da Silva, et JOSÉ BRUNO DA SILVA AZEVEDO. « REVISÃO BIBLIOGRÁFICA SOBRE A DOENÇA DO ALZHEIMER : HIPERFOSFORILAÇÃO DA PROTEÍNA TAU E DEPOSIÇÃO DO PEPTÍDEO β-AMILOSE. » Dans I Congresso Nacional de Pesquisas e Estudos Genéticos On-line. Revista Multidisciplinar em Saúde, 2022. http://dx.doi.org/10.51161/geneticon/8830.
Texte intégralSchwartz, Dauana, et Bruna Kuhn De Freitas Silva. « BIOSSENSORES NANOESTRUTURADOS PARA DETECÇÃO DE BIOMARCADORES EM DOENÇAS DE PERFIL NEUROLÓGICO ». Dans II Congresso Brasileiro de Biotecnologia On-line. Revista Multidisciplinar de Educação e Meio Ambiente, 2022. http://dx.doi.org/10.51189/conbiotec/45.
Texte intégral